Abbott's FreeStyle Libre 2 has been approved for use in the U.S. for adults and children (ages four and older) with diabetes. In Abbott's June 15, 2020 press release, Jared Watkin, senior vice president, Diabetes Care, Abbott commented: "We're thrilled to bring our next generation technology on our world-leading sensing platform to both children and adults with diabetes in the U.S. With unsurpassed 14-day accuracy and enhanced features including optional alarms at a fraction of the cost of other CGMs, Abbott's FreeStyle Libre 2 system will change the future of diabetes care in the U.S. the same way it has around the globe."
Highlights of the new iCGM system include:
FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning.
Now for children and adults with diabetes, this latest technology is the first and only iCGM that sustains performance for up to 14 days, providing trends, insights and actionable data.
The FreeStyle Libre 2 system includes a self-applied sensor (the size of two-stacked quarters) that is easy to apply and worn on the back of the upper arm, eliminating the need for painful fingersticks to test glucose levels.
The FreeStyle Libre 2 has already launched in several European countries and is coming to others soon. It is not yet known when the FreeStyle Libre 2 will officially roll out in the United States, though Abbott says it will be in the coming weeks.